A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance.
Timothy Anthony YapPatricia M LoRussoDeborah J WongSiwen Hu-LieskovanKyriakos P PapadopoulosJosefin-Beate HolzUrszula GrabowskaCristian GradinaruKin-Mei LeungSylwia MarshallClaire S ReaderRoslin RussellRichard C A SainsonClaire J SealChristopher J ShepherdFiona GermaschewskiDaniel R GliddonOmer SternLesley YoungNeil BrewisLouis KayitalireMichelle MorrowPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
FS118 was well tolerated with no DLTs observed up to and including 20 mg/kg QW. Further studies are warranted to determine clinical benefit in patients who have become refractory to anti-PD-(L)1 therapy.